In Georgia, the third-generation IVF technology is commonly referred to as PGD/PGS. It actually falls under the category of PGT (Pre-Genetic Testing). This technique helps improve the efficiency of single embryo transfers, but it isn't necessary for everyone. Let's clarify its benefits and limitations.
After the embryo has been cultured to the blastocyst stage, a small sample of trophoblast cells is taken for genetic testing. This can detect chromosomal abnormalities (PGT-A) or specific single-gene disorders (PGT-M/original PGD). In other words, it's like conducting a "health check" on the embryo before transplantation.
People who are older (with a high risk of recurrent miscarriages or abnormal embryos), carriers of chromosomal imbalances, those with a family history of single-gene disorders, and those who have experienced multiple failed attempts at transplantation are the main groups that would benefit from this procedure. However, younger individuals without any fertility issues may not need it.
For those who qualify, this screening can reduce miscarriages and ineffective embryo transfers caused by chromosomal abnormalities. It also increases the success rate of single embryo transfers and reduces the risk of passing on certain genetic diseases.
There is a very small risk of damage during the biopsy process. The test cannot eliminate all congenital abnormalities. Additionally, it increases laboratory costs and wait times. While it improves efficiency, it doesn't guarantee a healthy baby.
Local clinics have the capability to culture blastocysts and perform biopsies. Samples are usually sent to partner genetic testing laboratories. It's important to verify the qualifications of the testing institution, the format of the report, and the number of days required for processing.
Doctors should determine whether this procedure is necessary based on factors such as age, history of miscarriages, and genetic risks. Don't add this option blindly.